文献速递免疫规划传染病防控与疫情报告妇幼与学校卫生

全球风疹与先天性风疹综合征控制及消除进展(2012—2020年)

Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2012-2020.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-02-11

本文总结2012年至2020年全球风疹与先天性风疹综合征(CRS)控制及消除进展。含风疹疫苗(RCV)免疫规划的国家从132个(68%)增至173个(89%),2020年全球70%婴儿接种风疹疫苗;报告风疹病例从2012年94,277例降至2019年49,136例(下降48%),2020年进一步降至10,194例;93个(48%)国家已验证消除风疹。

要点

  • 含风疹疫苗免疫规划国家从2012年132个(68%)增至2020年173个(89%)。
  • 报告风疹病例从2012年94,277例降至2019年49,136例,降幅48%,2020年降至10,194例。
  • 93个(48%)国家已验证消除风疹,包括美洲区域全部国家。

核心结论

  • 为增加保护公平性并进一步推进消除风疹,尚未引入含风疹疫苗的21个国家应引入该疫苗。
  • 已引入含风疹疫苗的国家可通过高接种覆盖率和风疹及CRS监测实现并维持消除。
  • 六个WHO区域中四个已设立风疹消除目标;非洲区域和东地中海区域已表达消除承诺,应考虑设立目标。

研究设计与样本

  • 本文为全球进展报告,更新既往报告,总结2012年加速风疹控制活动启动至2020年全球风疹与CRS控制及消除进展。

主要发现

  • 194个WHO成员国中含风疹疫苗免疫规划国家从2012年132个(68%)增至2020年173个(89%)。
  • 2020年全球70%婴儿接种风疹疫苗。
  • 报告风疹病例从2012年94,277例降至2019年49,136例(下降48%),2020年进一步降至10,194例。
  • 93个(48%)国家已验证消除风疹,包括美洲区域全部国家。

关键数值与推荐

  • 全球疫苗行动计划2011—2020目标为到2020年至少六个WHO区域中的五个实现风疹消除。
  • WHO建议利用加速麻疹消除活动的机会引入含风疹疫苗。
  • 单剂含风疹疫苗可提供终身保护。

临床怎么用

  • 尚未引入含风疹疫苗的21个国家应引入该疫苗。
  • 已引入含风疹疫苗的国家可通过高接种覆盖率和风疹及CRS监测实现并维持消除。
  • 非洲区域和东地中海区域已表达消除承诺,应考虑设立风疹消除目标。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rubella virus is a leading cause of vaccine-preventable birth defects and can cause epidemics. Although rubella virus infection usually produces a mild febrile rash illness in children and adults, infection during pregnancy, especially during the first trimester, can result in miscarriage, fetal death, stillbirth, or an infant born with a constellation of birth defects known as congenital rubella syndrome (CRS). A single dose of rubella-containing vaccine (RCV) can provide lifelong protection against rubella (1). The Global Vaccine Action Plan 2011-2020 (GVAP) included a target to achieve elimination of rubella in at least five of the six World Health Organization (WHO) regions* by 2020 (2), and WHO recommends capitalizing on the accelerated measles elimination activities as an opportunity to introduce RCV (1). This report updates a previous report (3) and summarizes global progress toward control and elimination of rubella and CRS from 2012, when accelerated rubella control activities were initiated, through 2020. Among 194 WHO Member States, the number with RCV in their immunization schedules has increased from 132 (68%) in 2012 to 173 (89%) in 2020; 70% of the world's infants were vaccinated against rubella in 2020. Reported rubella cases declined by 48%, from 94,277 in 2012 to 49,136 in 2019, and decreased further to 10,194 in 2020. Rubella elimination has been verified in 93 (48%) of 194 countries including the entire Region of the Americas (AMR). To increase the equity of protection and make further progress to eliminate rubella, it is important that the 21 countries that have not yet done so should introduce RCV. Likewise, countries that have introduced RCV can achieve and maintain rubella elimination with high vaccination coverage and surveillance for rubella and CRS. Four of six WHO regions have established rubella elimination goals; the two WHO regions that have not yet established an elimination goal (the African [AFR] and Eastern Mediterranean [EMR] regions) have expressed a commitment to rubella elimination and should consider establishing a goal.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Zimmerman LA, Knapp JK, Antoni S, et al. Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2012-2020. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35143468. doi:10.15585/mmwr.mm7106a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。